GT201200082A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Info

Publication number
GT201200082A
GT201200082A GT201200082A GT201200082A GT201200082A GT 201200082 A GT201200082 A GT 201200082A GT 201200082 A GT201200082 A GT 201200082A GT 201200082 A GT201200082 A GT 201200082A GT 201200082 A GT201200082 A GT 201200082A
Authority
GT
Guatemala
Prior art keywords
compositions
methods
bacterial infections
ceftaroline
treat bacterial
Prior art date
Application number
GT201200082A
Other languages
English (en)
Inventor
Thye Dirk
Talbot George
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200082(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of GT201200082A publication Critical patent/GT201200082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES QUE COMPRENDEN CEFTAROLINA O UN PROFÁRMACO DE ÉSTA (CEFTAROLINA FOSAMILO) Y MÉTODOS PARA TRATAR INFECCIONES BACTERIANAS, TALES COMO INFECCIONES COMPLICADAS DE LA PIEL Y SUS ESTRUCTURAS ADEMÁS DE NEUMONÍA BACTERIANA ADQUIRIDA EN LA COMUNIDAD (NBAC)
GT201200082A 2009-09-21 2012-03-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina GT201200082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
GT201200082A true GT201200082A (es) 2014-12-22

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200082A GT201200082A (es) 2009-09-21 2012-03-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Country Status (23)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20171176A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
MX361020B (es) 2011-06-17 2018-11-26 Pfizer Anti Infectives Ab Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
ES2323759T3 (es) * 2000-08-10 2009-07-24 Takeda Pharmaceutical Company Limited Compuesto de fosfonocefem.
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
EP2266590A3 (en) * 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
CN103919720A (zh) * 2007-09-21 2014-07-16 阿斯利康(瑞典)有限公司 适合肠胃外给药的包含头孢烯衍生物的可溶剂型

Also Published As

Publication number Publication date
HN2012000585A (es) 2015-06-15
CA2774772A1 (en) 2011-03-24
CR20120137A (es) 2012-05-28
EA029149B1 (ru) 2018-02-28
BR112012006250B1 (pt) 2021-07-06
NI201200045A (es) 2012-11-02
EP2480236A1 (en) 2012-08-01
ZA201202924B (en) 2012-12-27
US20110071114A1 (en) 2011-03-24
SG178936A1 (en) 2012-04-27
US9629861B2 (en) 2017-04-25
CO6531417A2 (es) 2012-09-28
US20150258126A1 (en) 2015-09-17
ECSP12011739A (es) 2012-05-30
KR20120083344A (ko) 2012-07-25
EP2480236A4 (en) 2013-04-17
AU2010295269B2 (en) 2014-06-05
PE20121819A1 (es) 2013-02-01
BR112012006250A2 (pt) 2016-05-31
AU2010295269A1 (en) 2012-04-12
PE20171176A1 (es) 2017-08-22
CN102781451A (zh) 2012-11-14
MX2012003201A (es) 2012-05-08
MX2012003411A (es) 2012-04-30
CU20120048A7 (es) 2012-10-15
DOP2012000077A (es) 2012-05-31
EA201200501A1 (ru) 2012-10-30
IL218349A0 (en) 2012-04-30
WO2011035305A1 (en) 2011-03-24
CL2012000694A1 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
UY34100A (es) INMUNOCONJUGADOS DEL PROFARMACO seco-MGBA, COMPOSICIONES Y MÉTODOS PARA PREPARARLOS, Y SUS USOS
GB2511713B (en) Compositions for the treatment of bone fragility
MX345514B (es) Composiciones pesticidas.
MX2021004211A (es) Composiciones vacuna.
IN2014DN11201A (es)
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
UY33909A (es) Metodo para producir fibra de lignina
MX2018015349A (es) Sintesis de fibra elastica in vivo.
BR112015009301A2 (pt) biocontrole de nematoides
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX350392B (es) Aceite de sandalo y sus usos.
UY32075A (es) Estabilización de preparaciones acuosas de minerales mediante reuterina
MX339361B (es) Derivados de alternano.
MX336018B (es) Uso de propineb como repelente de aves.
GT201200082A (es) Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina
MX347541B (es) Analogos de acido sialico.
MX342239B (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
BR112012026542A2 (pt) abordagem seletiva de tecido
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
WO2012116992A3 (en) Oral use of a composition comprising steviol or isosteviol
IN2014DN03298A (es)
EA201401087A1 (ru) Композиция для личной гигиены